Last reviewed · How we verify
Hookah
Hookah is a Small molecule drug developed by University of California, San Francisco. It is currently in Phase 1 development. Also known as: participant will smoke hookah.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hookah |
|---|---|
| Also known as | participant will smoke hookah |
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Developing and Pilot Testing an Intervention to Reduce Household Shisha Smoke Exposure Within Somali Homes (NA)
- Electronic Hookah and Endothelial Cell Function (NA)
- A Study of Hookah Café Customers in the Atlanta Area (NA)
- Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol (NA)
- Reactions to Warnings on Hookah Ads (NA)
- Effect of Waterpipe Size on Smoking Behavior and Exposures (NA)
- Oxidative DNA Damage Enhancement by Vitamin C Among Narghile Smokers and Non-smokers (NA)
- Evaluating the Efficacy of a Text Messaging-based Shisha Smoking Cessation Intervention (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hookah CI brief — competitive landscape report
- Hookah updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Hookah
What is Hookah?
Who makes Hookah?
Is Hookah also known as anything else?
What development phase is Hookah in?
Related
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: participant will smoke hookah
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing